Matthew Kamin, DO
Cardiovascular Disease · Olympia Fields, ILNPI 1043203862
Payments from drug & device makers
Across 564 payments — averaging $54.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$19K
- Johnson & Johnson$2K
- E.r. Squibb & Sons, L.L.C.$1K
- Novartis$1K
- Boehringer Ingelheim$1K
- AstraZeneca$761
- plus $5K from 28 others
What the payments were for
- Speaking & faculty fees$15,28650%
- Travel & lodging$2,2267%
- Food & beverage$13,28243%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 67 | $19,400 |
| Johnson & Johnson | 82 | $1,811 |
| E.r. Squibb & Sons, L.L.C. | 45 | $1,400 |
| Novartis | 94 | $1,393 |
| Boehringer Ingelheim | 39 | $1,355 |
| AstraZeneca | 25 | $761 |
| Boston Scientific | 25 | $657 |
| Pfizer | 32 | $586 |
| Merck | 19 | $543 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 35 | $502 |
| Novo Nordisk | 13 | $401 |
| Lexicon Pharmaceuticals, Inc. | 16 | $389 |
| Esperion Therapeutics, Inc. | 16 | $276 |
| Scpharmaceuticals Inc. | 9 | $196 |
| Amarin Pharma, Inc. | 10 | $168 |
| Abiomed | 3 | $162 |
| Alnylam Pharmaceuticals Inc. | 5 | $121 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $112 |
| Abbott | 4 | $99 |
| Inspire Medical Systems, Inc. | 1 | $82 |
| Kowa Pharmaceuticals America, Inc. | 4 | $62 |
| Bayer | 3 | $55 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Ionis Pharmaceuticals, Inc. | 1 | $32 |
| Biotronik Inc. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $20 |
| Mannkind Corporation | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Terumo Medical Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,795 in reported general payments places this provider in the 85th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 500 | $616,251 |
| Repatha SureclickEvolocumab | 701 | $524,409 |
| EntrestoSacubitril/Valsartan | 322 | $443,949 |
| EliquisApixaban | 307 | $387,972 |
| VyndamaxTafamidis | 12 | $276,077 |
| JardianceEmpagliflozin | 146 | $178,460 |
| Praluent PenAlirocumab | 211 | $143,212 |
| FarxigaDapagliflozin Propanediol | 40 | $34,064 |
| Ezetimibe | 990 | $26,146 |
| NexlizetBempedoic Acid/Ezetimibe | 25 | $24,060 |
| VascepaIcosapent Ethyl | 40 | $19,828 |
| Ranolazine ErRanolazine | 171 | $19,398 |
| Metoprolol Succinate | 899 | $15,789 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 45 | $15,272 |
| Rosuvastatin Calcium | 1,040 | $14,880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $586 | $664,049319 claims |
| Johnson & JohnsonXarelto | $1,811 | $616,251500 claims |
| NovartisEntresto | $1,393 | $443,949322 claims |
| Boehringer IngelheimJardiance | $1,355 | $178,460146 claims |
| AstraZenecaFarxiga | $761 | $34,06440 claims |
| Esperion Therapeutics, Inc.Nexlizet | $276 | $24,06025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Olympia Fields
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Lokesh ChandraHazel Crest$2.7M
- Steven LupovitchArlington Heights$2.6M
- Nitasha SarswatChicago$2M
- Alan BrownNaperville$1.5M
- Alexander AdlerPeoria$1.5M
- Clifford KavinskyMaywood$1.4M
- Sanjiv ShahChicago$1.2M
- Sandeep NathanChicago$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.